SYDNEY, June 29 /PRNewswire-Asia/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced it had raised A$7.2 million from its Share Purchase Plan which closed on 24 June 2009. Shareholders of the company were given the opportunity to purchase up to $5,000 worth of shares each at the $2.35 price paid by institutional investors in the recent placement.
A total of 1,584 shareholders participated in the plan under which the company will issue approximately 3 million new shares and receive funds of approximately $7.2 million.
Dr Alan Robertson, Chief Executive Officer of Pharmaxis said, "We are very encouraged and appreciative of the level of support from our shareholders. The total proceeds of the placement and share purchase plan of $54 million puts us in a strong position from which to take our products to the global markets."
Shares will be issued today, 30 June 2009, and are expected to be listed on the Australian Securities Exchange on 2 July 2009. Holding statements will be posted on or about 1 July 2009.
The statements contained in this media release that are not purely
historical are forward-looking statements within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended. Forward-looking statements in
this media release include statements regarding our expectations, beliefs,
hopes, goals, intentions, initiatives or strategies, including statements
regarding the potential for Aridol and/or Bronchitol. All forward-looking
statements included in this media release are based upon information available
to us as of the date hereof, and we assume no obligation to update any such
forward-looking statement as a result of new information, future events or
otherwise. We cannot guarantee that any product candidate will receive
|SOURCE Pharmaxis Ltd|
Copyright©2009 PR Newswire.
All rights reserved